CA Patent

CA2171728C — Triaryl-ethylene derivatives for use in therapy

Assigned to Aventis Pharmaceuticals Inc · Expires 2001-11-13 · 25y expired

What this patent protects

The present invention relates to novel triaryl-ethylene derivatives that are useful as anti-neoplastic agents, antiatherosclerotic agents, and hypocholesterolemic agents.

USPTO Abstract

The present invention relates to novel triaryl-ethylene derivatives that are useful as anti-neoplastic agents, antiatherosclerotic agents, and hypocholesterolemic agents.

Drugs covered by this patent

Patent Metadata

Patent number
CA2171728C
Jurisdiction
CA
Classification
—
Expires
2001-11-13
Drug substance claim
No
Drug product claim
No
Assignee
Aventis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.